Figure 2.

Mepolizumab prevents an allergen-induced rise in circulating eosinophils. (A) Before administration of mepolizumab, there was a significant rise in circulating eosinophil counts 48 hours (D2) after airway allergen challenge. The allergen-induced rise did not occur when challenge was given 1 month postmepolizumab. (B) WBC counts were not changed by allergen challenge or mepolizumab. Data represent medians with first and third quartiles; whisker lines represent the 10th and 90th percentiles (n = 10). Pre- versus postallergen P values are indicated above the solid lines; pre- versus postmepolizumab P values are indicated above the dashed lines. D0, D2 = Day 0, Day 2; ns = not significant; preAg = before segmental allergen challenge; WBC = white blood cells.